Pui San Kwan Sells 18,941 Shares of ChemoCentryx Inc (NASDAQ:CCXI) Stock

ChemoCentryx Inc (NASDAQ:CCXI) insider Pui San Kwan sold 18,941 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $49.15, for a total transaction of $930,950.15. Following the sale, the insider now directly owns 493 shares in the company, valued at approximately $24,230.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pui San Kwan also recently made the following trade(s):

  • On Thursday, January 16th, Pui San Kwan sold 89,179 shares of ChemoCentryx stock. The stock was sold at an average price of $39.91, for a total transaction of $3,559,133.89.
  • On Friday, January 10th, Pui San Kwan sold 1,000 shares of ChemoCentryx stock. The shares were sold at an average price of $39.02, for a total transaction of $39,020.00.
  • On Monday, January 6th, Pui San Kwan sold 122,912 shares of ChemoCentryx stock. The shares were sold at an average price of $34.57, for a total transaction of $4,249,067.84.

Shares of NASDAQ:CCXI opened at $48.00 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $2.79 billion, a PE ratio of -52.17 and a beta of 2.40. The firm’s 50 day moving average price is $41.39 and its 200-day moving average price is $19.90. ChemoCentryx Inc has a twelve month low of $6.16 and a twelve month high of $49.97.

Several brokerages recently issued reports on CCXI. Canaccord Genuity raised their target price on shares of ChemoCentryx from $16.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Piper Jaffray Companies boosted their target price on shares of ChemoCentryx from $17.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. Raymond James raised their price target on ChemoCentryx from $17.00 to $56.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, November 26th. BidaskClub upgraded ChemoCentryx from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, HC Wainwright lifted their price objective on ChemoCentryx from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $43.14.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC increased its holdings in ChemoCentryx by 4.2% during the second quarter. Parametric Portfolio Associates LLC now owns 57,809 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 2,319 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of ChemoCentryx by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,774,489 shares of the biopharmaceutical company’s stock worth $16,502,000 after acquiring an additional 488,063 shares during the last quarter. Invesco Ltd. boosted its stake in shares of ChemoCentryx by 8.5% during the 2nd quarter. Invesco Ltd. now owns 161,723 shares of the biopharmaceutical company’s stock worth $1,504,000 after acquiring an additional 12,735 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of ChemoCentryx by 7.0% during the 2nd quarter. Bank of America Corp DE now owns 99,304 shares of the biopharmaceutical company’s stock worth $923,000 after acquiring an additional 6,487 shares during the last quarter. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of ChemoCentryx during the 2nd quarter valued at $201,000. Institutional investors own 60.57% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

Featured Article: Google Finance Portfolio

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.